S&P Futures
4,142.50 +0.75 (+0.02%) Dow Futures
32,808.00 +16.00 (+0.05%) Nasdaq Futures
13,173.75 -9.50 (-0.07%) Russell 2000 Futures
1,943.20 +2.10 (+0.11%) Crude Oil
89.45 -1.31 (-1.44%) Gold
1,805.00 -0.20 (-0.01%)
Viking Therapeutics, Inc. (VKTX)
Chart Events
Performance Outlook
| Previous Close | 3.4300 |
| Open | 3.4700 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.4100 - 3.5900 |
| 52 Week Range | 2.0200 - 7.2000 |
| Volume | |
| Avg. Volume | 1,172,879 |
| Market Cap | 279.299M |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7060 |
| Earnings Date | Apr 26, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.56 |
- Simply Wall St.
What Is The Ownership Structure Like For Viking Therapeutics, Inc. (NASDAQ:VKTX)?
Every investor in Viking Therapeutics, Inc. ( NASDAQ:VKTX ) should be aware of the most powerful shareholder groups...
- PR Newswire
Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.
- Motley Fool
Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript
Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 27, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones.
